Approved for use through 10/31/2002. OMB 0651-0031*

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a vertal IMB control number. Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

	C mplete if Kn wn	空 品
Application Number	10/049,464	3.0
Filling Date	6/18/2002	700
First Named Inventor	HUENIG	H O II
Group Art Unit	1614	30 0
Examiner Name	Unassigned	9 9
Attorney Docket Number	ALBRE-23	음 ~
-		<u> </u>

				U.S. PATENT DOCUM	MENTS	0
		U.S. Pa	tent Document	Name of Patentae or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevar
Examiner Initials *	Cite No. ¹	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	1	5;858; 3	58	June et al.	01-12-1999	
61	PE					
SEP 0	3 2002	<u> </u>				
THA THA	DENN AY	/				
	ı	1				

				FOREIG	N PATENT DOCU	MENTS		
Examiner Cite Initials* No.	Cita	Foreign Patent Docume		Marile or Faterities		Date of Publication of	Pages, Columns, Lines, Where Relevant	
	No.1	Office ³	Number ⁴	Kind Code ⁶ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Ta
	-2	-wo-	98 1731	3.		04-30-1998		
	3	wo	94 0647	3		03-13-1994		
	4	DE-	-197 22 8	88 -		12-03-1998		
==	- 3	wo	94/2943	61		12-22-1994		
					<u> </u>			
								
								

Examiner Signature	Ilia	Owel	sehl	Date Considered	11/	08/	2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Approved for use through PREV/2002. OMB 3691-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMPLERCE

Under the Paperwork Reduction Act of 1995, no persons are require

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 2

lectures rollestours as a consciou or	Toomaton weess it contain	I S & ASTO GOVED COULD	or on urbe
	C mplete if Know	WITT PO	S S
Application Number	10/049,464	# 0	皿
Filing Date	06-18-2002	20 0	Z
First Named Inventor	HUENIG	5 8	$\overline{\Pi}$
Group Art Unit	1614	0, 2	
Examiner Name	Unassigned	100	
Attorney Docket Number	ALBRE-23	8	

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
	-0-	M.HEZAREEH ET AL., *Differential T Cell Induction of Productive HIV Replication in Samples From Patients on Prolonged Suppressive Therapy*, <u>CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS</u> , 1998, pg. 183-Vol-5	
	7	U. HENGGE ET AL., Randomized, Controlled Phase II Trial of Subcutaneous Interleukin-2 in Combination With Highly Active Antiretroviral Therapy (Haart) in HIV Patlents*, 1998, pp. F225-F234, Vol. 12, No. 17	
	0	T-W CHUN ET AL., 'Effect of Interleukin-2 on the Pool of Latently Infected, Resting CD4+ T Cellsin HIV-1-Infected Patients Receiving Highly Active Anti-Retroviral Therapy'. NATURE MEDICINE, June 6, 1899, pp. 651-655, Vol. 5, No. 6	
I.O.	9	T-W CHUN ET AL, "Quantification of Latent Tissue Reservoirs and Total Body Viral Load in HIV-1 Infection", NATURE May 8, 1997, pp 183-188, Vol 387, No. 6629	
	10	E. Barker et al., "CD28 Costimulation Increases CD8+ Cell Suppression of HIV Replication", The JOURNAL OF IMMUNOLOGY, November 15, 1997, pp.51213-5131, Vol. 159, No. 10	
		·	

Examiner Signature	Thia	Oulpen	لم	Date Considered	il	/ 08/	2005	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.